Form 4: Madrigal Pharmaceuticals CEO Sells Shares
Insider Transaction (Form 4)
William John Sibold, President and CEO and a Director of Madrigal Pharmaceuticals, Inc., sold 2,500 shares of common stock on July 17, 2026.
Summary
- Option exercise/conversion: acquired 50,000 Common Stock on July 17, 2026; holds 211,829 after (Direct).
- Open-market sale: disposed of 140 Common Stock at $542.75 ($75,984) on July 20, 2026; holds 211,689 after (Direct).
- Open-market sale: disposed of 110 Common Stock at $543.79 ($59,817) on July 20, 2026; holds 211,579 after (Direct).
- Open-market sale: disposed of 545 Common Stock at $544.71 ($296,869) on July 20, 2026; holds 211,034 after (Direct).
- Open-market sale: disposed of 275 Common Stock at $545.71 ($150,070) on July 20, 2026; holds 210,759 after (Direct).
- Open-market sale: disposed of 269 Common Stock at $547.08 ($147,164) on July 20, 2026; holds 210,490 after (Direct).
- Open-market sale: disposed of 680 Common Stock at $547.70 ($372,435) on July 20, 2026; holds 209,810 after (Direct).
- Open-market sale: disposed of 47 Common Stock at $548.87 ($25,797) on July 20, 2026; holds 209,763 after (Direct).
- Open-market sale: disposed of 153 Common Stock at $550.01 ($84,152) on July 20, 2026; holds 209,610 after (Direct).
- Open-market sale: disposed of 1 Common Stock at $550.72 ($551) on July 20, 2026; holds 209,609 after (Direct).
- Open-market sale: disposed of 280 Common Stock at $555.05 ($155,414) on July 20, 2026; holds 209,329 after (Direct).
- Option exercise/conversion: disposed of 50,000 Performance Restricted Stock Units on July 17, 2026 (Direct).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,368,253 of stock on the open market.
Insider Transactions
William John Sibold — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Option exercise/conversion | Common Stock | 50,000 | — | — | 211,829 |
| 2026-07-20 | Open-market sale | Common Stock | 140 | $543 | $76.0K | 211,689 |
| 2026-07-20 | Open-market sale | Common Stock | 110 | $544 | $59.8K | 211,579 |
| 2026-07-20 | Open-market sale | Common Stock | 545 | $545 | $296.9K | 211,034 |
| 2026-07-20 | Open-market sale | Common Stock | 275 | $546 | $150.1K | 210,759 |
| 2026-07-20 | Open-market sale | Common Stock | 269 | $547 | $147.2K | 210,490 |
| 2026-07-20 | Open-market sale | Common Stock | 680 | $548 | $372.4K | 209,810 |
| 2026-07-20 | Open-market sale | Common Stock | 47 | $549 | $25.8K | 209,763 |
| 2026-07-20 | Open-market sale | Common Stock | 153 | $550 | $84.2K | 209,610 |
| 2026-07-20 | Open-market sale | Common Stock | 1 | $551 | $551 | 209,609 |
| 2026-07-20 | Open-market sale | Common Stock | 280 | $555 | $155.4K | 209,329 |
| 2026-07-17 | Option exercise/conversion | Performance Restricted Stock Units | 50,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Option exercise/conversion (50,000 shares) |
| 2026-07-20 | Open-market sale (140 shares) |
| 2026-07-20 | Open-market sale (110 shares) |
| 2026-07-20 | Open-market sale (545 shares) |
| 2026-07-20 | Open-market sale (275 shares) |
| 2026-07-20 | Open-market sale (269 shares) |
| 2026-07-20 | Open-market sale (680 shares) |
| 2026-07-20 | Open-market sale (47 shares) |
| 2026-07-20 | Open-market sale (153 shares) |
| 2026-07-20 | Open-market sale (1 shares) |
| 2026-07-20 | Open-market sale (280 shares) |
| 2026-07-17 | Option exercise/conversion (50,000 shares) |
Keywords
insider transaction, Form 4, MDGL, MADRIGAL PHARMACEUTICALS, INC., bearish, William John Sibold
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.